华特达因(000915) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the reporting period reached ¥1,011,340,076.40, representing a 21.45% increase compared to ¥832,723,482.58 in the same period last year[25]. - Net profit attributable to shareholders was ¥229,228,221.75, a significant increase of 69.80% from ¥134,998,363.12 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was ¥221,394,750.77, up 73.07% from ¥127,921,739.31 year-on-year[25]. - Basic earnings per share increased to ¥0.98, up 68.97% from ¥0.58 in the same period last year[25]. - The net profit for the period was ¥421,598,252.16, marking a significant increase of 68.54% from ¥250,143,506.03, primarily due to profit growth from the subsidiary, Dain Pharmaceutical[44]. - The company's operating profit for the first half of 2021 was CNY 490,923,004.16, up from CNY 293,152,306.72 in the previous year, reflecting a growth of approximately 67.3%[151]. Cash Flow and Assets - The net cash flow from operating activities was ¥337,780,624.10, reflecting a 5.31% increase from ¥320,744,856.25 in the previous year[25]. - The company's total assets at the end of the reporting period were ¥3,846,179,904.13, a 4.09% increase from ¥3,694,977,604.81 at the end of the previous year[25]. - Cash and cash equivalents decreased by ¥573,898,803.13, a decline of 40.83% compared to the previous period, mainly due to increased investments in bank financial products[44]. - The total cash and cash equivalents at the end of the period amounted to 908,816,393.15 yuan, down from 1,482,715,196.28 yuan at the beginning of the period[157]. - The company reported a decrease in cash and cash equivalents by -573,898,803.13 yuan, compared to -407,489,710.43 yuan in the previous period[157]. Business Operations - Revenue from the pharmaceutical sector amounted to 749 million yuan, accounting for 74.03% of the company's main business income[33]. - The pharmaceutical subsidiary, Dain Pharmaceutical, achieved a revenue growth of 27% year-on-year, with a net profit of 392 million yuan, up 66%[38]. - The company is focused on children's health products, with a product lineup that includes well-known brands like Yike Xin, which holds the largest market share in its category[34]. - Dain Pharmaceutical focuses on children's medicine and has improved production efficiency by importing core equipment from Germany and Italy, enhancing automation levels[67]. - The company is exploring strategic investments in raw material pharmaceutical companies to secure supply chains and mitigate risks associated with price reductions in children's medicines[67]. Research and Development - The company applied for a total of 33 intellectual property rights in the first half of 2021, with 18 being granted[38]. - Research and development expenses amounted to ¥29,827,217.69, showing a decrease of 4.67% from ¥31,288,647.52[44]. - Dain Pharmaceutical plans to continue enhancing research and innovation to diversify its children's medicine product offerings and strengthen its market position[67]. Governance and Compliance - The company is actively participating in state-owned enterprise reforms to optimize its governance structure and enhance operational efficiency[37]. - The company has not engaged in any significant related party transactions during the reporting period[91]. - There were no major litigation or arbitration matters during the reporting period[90]. - The company has adhered to all commitments made regarding competition avoidance and has completed relevant procedures[84]. Environmental Responsibility - The company has implemented an environmental self-monitoring plan, including online monitoring of wastewater discharge and regular third-party testing, with all results meeting standards[80]. - The company completed environmental impact assessments for its construction projects, with the first phase approved in November 2008 and environmental acceptance completed in December 2011[78]. - There were no administrative penalties due to environmental issues during the reporting period[81]. Shareholder Information - The company's stock structure includes 234,331,485 shares, with 99.93% being unrestricted shares[114]. - The largest shareholder, Shandong Huate Holding Group Co., Ltd., held 22.00% of the shares, totaling 51,544,340 shares[125]. - The total number of common shareholders at the end of the reporting period was 20,235[118]. - The company has not distributed any profits to shareholders, with a total profit distribution of -70,299,445.50[194].